This high-flying chip stock is poised for another big year.
The commercial engine behind this performance is largely driven by tirzepatid. Sold under the brand names Mounjaro and Zepbound, the drug generated $36.51 billion in revenue during 2025, surpassing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results